In February 2017, NPPA capped coronary stent prices by up to 85 per cent through a notification, triggering multinational exits; months later it invoked Paragraph 19 of the DPCO 2013 to cap knee implants. In June 2026 that power moved the other way: a one-time 50 per cent ceiling increase for carboplatin and cisplatin, to hold supply. The standard National List of Essential Medicines formula coexists with a power invocable for any product on public interest grounds. Two ministries operate the architecture; no appellate tribunal sits outside the Authority. How must a pharmaceutical company modelling India revenue read it?
If BIS shapes market access through product standards, the National Pharmaceutical Pricing Authority shapes it through price. India's pharmaceutical pricing architecture operates through two layers that were designed independently and interact in ways that most companies do not fully map until a pricing action affects their portfolio.
The first layer is the National List of Essential Medicines (NLEM). The NLEM is revised periodically by an expert committee constituted by the Ministry of Health and Family Welfare, which evaluates therapeutic essentiality, disease burden, availability, and affordability. When a drug is included in the NLEM, it becomes a "scheduled drug" under the Drug Prices Control Order (DPCO) 2013, and its price is subject to a ceiling calculated by the National Pharmaceutical Pricing Authority (NPPA). The ceiling price formula is market-derived, not cost-based: it is computed as the simple average of prices of all brands with a market share greater than 1% of the total market for that formulation. A company that has invested in brand-building and commands a premium price is averaged with generic competitors. The ceiling compresses the range; the premium erodes.
The 1% market share threshold inside the ceiling formula has a specific institutional consequence in categories with active biosimilar entry. Trastuzumab, for example, is manufactured by roughly 15 companies in the Indian market, but only two cross the 1% share bar; the remaining manufacturers, which include most of the biosimilar entrants, are excluded from the ceiling calculation entirely. The ceiling tracks the premium incumbents; the biosimilars compete below it but the scheduled-drug patient does not experience the competitive price. The pre-2013 DPCO used a cost-plus formula anchored to manufacturing cost; the 2013 shift to market-based pricing was made in the direction of domestic manufacturing viability at a moment when cost-plus ceilings were pushing Indian producers toward Chinese API dependence. The shift unanchored the ceiling from manufacturing cost, and MRPs in several oncology categories now sit at multiples of that cost.
The NLEM revision process is itself consequential. The expert committee's deliberations are not transparent to industry until the revised list is published. A pharmaceutical company modelling India revenue on the assumption that its product is non-scheduled may discover that the next NLEM revision brings it under ceiling price control. The movement from non-scheduled to scheduled is a binary event with immediate financial consequence, and the company's ability to anticipate it depends on whether it is tracking the institutional signals; which therapeutic categories are under review, what the committee's composition suggests about its priorities, and whether the disease burden data supports inclusion.
The second layer is where most pharmaceutical companies are caught unprepared.
Paragraph 19 of the DPCO 2013 empowers the Government to fix the ceiling price or retail price of any drug in "extraordinary circumstances in the public interest" for such period as it deems fit. The scope of what constitutes "extraordinary circumstances" is not defined in the DPCO. NPPA has interpreted it broadly, using Paragraph 19 to fix ceiling prices for scheduled products where the standard market-based formula would not produce the desired ceiling, as well as for non-scheduled products outside the NLEM framework altogether. The courts have yielded mixed rulings on where the boundary lies.
The coronary stent intervention and the orthopaedic knee implant intervention are the most instructive cases. For coronary stents, NPPA capped prices through the standard route after their inclusion in the National List of Essential Medicines, compressing margins by up to 85 per cent in certain categories and triggering the withdrawal of premium stents from the Indian market. Six months later, NPPA invoked Paragraph 19 via S.O. 2668(E) to cap knee implants, reducing patient costs by up to 70 per cent. Both price caps were issued for a period of one year; both have been extended every year since. A time-bound extraordinary power, in operational practice, has become a rolling price regulation across multiple product categories. Cancer drugs have been subject to Paragraph 19 action on multiple occasions. The instructive feature is what these cases share: Paragraph 19 is not a backup for products missing from the NLEM; it is an independent pricing pathway NPPA has used to act on scheduled and non-scheduled products alike, on timelines and via data sources the standard DPCO formula does not reach. The pricing action arrived through an institutional pathway that the DPCO framework was not originally designed to accommodate as a routine instrument; but which NPPA has used repeatedly, establishing a de facto precedent that any product category with perceived affordability concerns can be brought under price control at any time.
The same power runs in the opposite direction when the risk is not price but supply. In June 2026, on a recommendation from a committee constituted under Paragraph 19 and with in-principle approval from the Department of Pharmaceuticals, NPPA granted a one-time 50 per cent increase in the ceiling prices of carboplatin and cisplatin, two first-line oncology injections, after reviewing active pharmaceutical ingredient (API) price trends across FY22 to FY26. A parallel 50 per cent increase was granted for anti-tetanus immunoglobulin, where a single domestic manufacturer carries the product. The stated logic was that import-dependent API costs and exchange-rate movement had made domestic manufacture unviable, and that non-availability would push patients toward costlier alternatives; the higher ceiling was, in expectation, the access-protective outcome. The revision carries a review after six months. The instrument the framework reads as a price-suppression power operates, in practice, as a two-way discretionary lever, and the constant across both directions is the Authority's discretion over what continued availability requires.
The methodology beneath these decisions is itself unsettled, and the pressure on it now comes from within the architecture. While relaxing some ceilings upward, NPPA continues to apply a monopoly reduction, a lower ceiling fixed for products with a single or dominant supplier, including to vaccines such as BCG, Measles-Rubella and Measles. Serum Institute of India has contested the method, arguing that biologicals cannot be benchmarked against chemical formulations in the same therapeutic category because each carries a distinct manufacturing process, technology and market. The Department of Pharmaceuticals, NPPA's own administrative department, has asked the Authority to reconsider, citing an earlier instance in the BCG vaccine where the monopoly reduction was not applied. The contest is not running through a tribunal; it is running through the parent department, which is where a company without a settled appellate forum must locate the argument.
The legal challenges have yielded an uneven record. Some courts have upheld NPPA's authority under Paragraph 19, accepting that public interest in affordable access to essential medical products constitutes extraordinary circumstances. Others have questioned whether the invocation was procedurally sound or whether NPPA exceeded its authority by effectively creating a parallel pricing regime outside the NLEM framework. The jurisprudence has not settled into a consistent position, which means the legal risk for pharmaceutical companies remains live.
The revision architecture and the appellate geometry together determine how a ceiling price can be engaged after it has been fixed, and this dimension of the NPPA architecture is institutionally distinctive. Paragraph 11 of the DPCO 2013 permits a manufacturer of a scheduled formulation to apply for ceiling price revision on documented movement in input costs, exchange rate impact, or changed market conditions; Paragraph 20 provides an analogous window for non-scheduled interventions. Applications are examined by the NPPA Review Committee, which issues either a revised Office Order or a formal rejection. The feature that defines matter-level engagement is what sits beyond the Review Committee: nothing statutory. No appellate tribunal has been constituted for NPPA price orders. CBIC has CESTAT, CCI has NCLAT, SEBI has SAT; NPPA has none. The only external remedy is writ jurisdiction at the High Court, and the Delhi High Court, which hears most NPPA matters by virtue of the Authority's seat, has been consistently deferential to the pricing methodology itself, intervening primarily on procedural grounds (non-consideration of relevant data, violation of natural justice) rather than on substantive calculation. The architectural consequence is that matter-level engagement with NPPA sits within NPPA itself. A revision representation that reads as margin advocacy fails; one that corrects NPPA's own input assumptions, surfaces an error in the Authority's data source, or documents a market movement the previous Order did not reflect, is the representation the Review Committee can act on. The absence of an external corrective forum is not an omission from the architecture; it is the architecture.
A two-ministry institutional dynamic sits behind the architecture. The Ministry of Health and Family Welfare, through the NLEM expert committee, determines what is therapeutically essential. The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, through NPPA, determines what the price should be. Health's institutional mandate is public health access; its evaluation framework prioritises disease burden and treatment availability. Pharmaceuticals' mandate includes industrial development, manufacturing competitiveness, and commercial viability of the sector. These two mandates do not always align, and the architecture provides no mechanism to reconcile them before a pricing decision is taken. A pricing decision that maximises access by compressing margins may undermine the commercial viability of manufacturing complex formulations where the margins are already thin. The NLEM committee and NPPA operate through different institutional processes, different consultation mechanisms, and different industry engagement patterns.
The deeper architectural limit of the NPPA framework, in oncology particularly, is that the Authority operates on the manufacturer-MRP layer while the price the patient actually pays is determined by an architecture the Authority does not reach. The NLEM 2022 covers 63 anti-cancer medicines, up from 40 in 2011, which still represents a minority of the oncology pharmacopoeia available in the Indian market. For the majority, manufacturer discounts flow through Patient Support Programmes, often compressing realised prices to 30-40 percent of the printed MRP, but the discount is captured by the hospital-captive pharmacy and the distributor rather than transmitted to the patient; the patient bill reflects the MRP. The oncology architecture compounds this: cancer drugs are prescribed by molecule rather than brand because treatment requires combination regimens, which means the hospital, not the physician and not the regulator, selects the brand dispensed, and the selection correlates with the hospital margin the brand offers. The 14th report of the Lok Sabha Standing Committee on Chemicals and Fertilisers, released in 2025, documented trade margins of 600 to 1,100 per cent on commonly prescribed medicines, including cancer medication, between hospital procurement and the patient bill, and recommended trade margin rationalisation; the recommendation sits at the Department of Pharmaceuticals. A second structural pressure keeps MRPs elevated: the Indian MRP functions as the reference price for the manufacturer's international market, and a high MRP is also the evidentiary basis a compulsory licensing application requires. The state's two principal affordability instruments, price control and compulsory licensing, both create incentives for the printed list price to sit high. A scheduled-drug ceiling at the MRP layer, or a Budget-level fiscal relief such as the Basic Customs Duty abolition on select cancer medicines, reduces the landed or list price without necessarily reducing the patient bill, because the distribution architecture absorbs the differential. The Delhi High Court Division Bench's January 2026 ruling in Zydus Lifesciences versus E.R. Squibb & Sons on Nivolumab, upheld by the Supreme Court in February 2026, vacated the interim injunction against Zydus's biosimilar on the ground that where a product is life-saving the court must err in favour of public interest. That reasoning is a judicial signal that the IP-affordability calibration is now shifting in the courts as well as in NPPA's Paragraph 19 invocations. The regulatory, fiscal, and judicial instruments the Indian state has built to deliver affordability all operate on the layer the state has jurisdictional purchase over; the layer that determines what the patient pays sits downstream of that purchase, and closing the distance between the two requires an institutional architecture that does not yet exist.
The pharmaceutical company that engages with NPPA on pricing but does not track the NLEM committee's proceedings may be blindsided by an inclusion that restructures its entire India pricing architecture.
For any pharmaceutical company modelling India as a revenue market, three institutional realities must be factored in. First, the NLEM is not static; every revision carries the potential to bring additional products under ceiling price control. Second, Paragraph 19 means that even non-scheduled drugs are not outside the reach of price regulation; NPPA has demonstrated willingness to intervene when public interest, however broadly interpreted, is invoked. Third, the pricing action, when it comes, is immediate; a single NPPA notification can compress margins across an entire product category overnight, with no transition period and no grandfathering of existing contracts.
The Indian pharmaceutical pricing regime does not operate the way most global companies assume pricing regulation works. It is not a transparent, predictable framework where controlled products are identified in advance and pricing rules are applied consistently. It is a dual-track system where the standard framework (NLEM plus ceiling price) coexists with an extraordinary power (Paragraph 19) that can be invoked for any product, at any time, based on a public interest determination that is neither precisely defined nor consistently adjudicated. The companies that manage this successfully are those that track both institutional tracks simultaneously and engage with the pricing architecture before the notification is issued, not after.